NCT03258424View on ClinicalTrials.gov

Study Assessing PTI-428 Safety, Tolerability, and Pharmacokinetics in Subjects With Cystic Fibrosis on KALYDECO® as Background Therapy

PHASE1CompletedINTERVENTIONAL
Enrollment

15

Participants

Timeline

Start Date

July 28, 2017

Primary Completion Date

October 3, 2018

Study Completion Date

October 3, 2018

Conditions
Cystic Fibrosis
Interventions
DRUG

PTI-428

PTI-428 or placebo will be given QD for 14 days.

DRUG

Placebo

PTI-428 or placebo will be given QD for 14 days.

Trial Locations (2)

BT9 6AD

Celerion, Belfast

Unknown

Medicines Evaluation Unit, Manchester

All Listed Sponsors
lead

Proteostasis Therapeutics, Inc.

INDUSTRY

NCT03258424 - Study Assessing PTI-428 Safety, Tolerability, and Pharmacokinetics in Subjects With Cystic Fibrosis on KALYDECO® as Background Therapy | Biotech Hunter | Biotech Hunter